Compare CE & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CE | LEGN |
|---|---|---|
| Founded | 1918 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.6B |
| IPO Year | 2004 | 2020 |
| Metric | CE | LEGN |
|---|---|---|
| Price | $48.70 | $16.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 14 |
| Target Price | ★ $63.39 | $40.93 |
| AVG Volume (30 Days) | 1.4M | ★ 2.4M |
| Earning Date | 11-02-2026 | 11-10-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | ★ 23.62 | N/A |
| EPS | ★ 2.21 | N/A |
| Revenue | ★ $9,544,000,000.00 | N/A |
| Revenue This Year | $4.47 | $38.78 |
| Revenue Next Year | N/A | $17.61 |
| P/E Ratio | $22.16 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.39 | $15.97 |
| 52 Week High | $70.70 | $37.50 |
| Indicator | CE | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 34.08 |
| Support Level | $43.28 | N/A |
| Resistance Level | $49.63 | $19.92 |
| Average True Range (ATR) | 2.19 | 1.40 |
| MACD | -0.06 | -0.75 |
| Stochastic Oscillator | 33.90 | 4.27 |
Celanese is a global specialty chemicals manufacturer. It operates in two segments: acetyl chain, and engineered materials. Acetyl chain profitability is exposed to commodity-linked raw materials and product pricing spreads. Engineered materials converts basic chemicals into higher-margin specialty polymers and compounds engineered for specific customer applications in automotive, medical, electronics, and industrial end markets.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.